$MGNX

On Aug. 11, Gilead Sciences (GILD) exercised an option to exclusively license a preclinical solid-tumor bispecific program using MacroGenics’ (MGNX) TRIDENT platform, triggering a $10 million milestone. The 2022 collaboration covers three programs, including clinical-stage MGD024, with up to $1.6 billion in milestones plus royalties. Financially, MGNX reported $20.8M Q1 revenue and $154.2M cash; GILD reported $7.8B Q2 revenue and raised 2026 product sales guidance to $29.8B–$30.1B.

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit99-1earningspressre.htm EX-99.1 Document Exhibit 99.1 MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position • Announced sale of manufacturing operations (July 2026) for $122.5 million and transi

MacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.

MacroGenics said it reached a $10 million milestone after Gilead exercised an option to license a preclinical bispecific program, according to the company. The announcement links the payment to Gilead’s licensing decision and may affect MacroGenics’ near-term cash flows and pipeline monetization.

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. mgnx-20260701 0001125345 FALSE 0001125345 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and

Sanofi SA (SNY) said it will appoint Paulo Fontoura as EVP and Global Head of R&D Pharma effective Sept. 1, reporting to CEO Belen Garijo and succeeding Houman Ashrafian. Separately, MacroGenics said it is entitled to $24.5M in regulatory milestone payments from Sanofi after FDA accelerated approval of TZIELD (teplizumab) for children.

Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ Rockville, Maryland GMP biologics drug-substance facility and a Frederick warehousing center for $122.5m via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics. Bora Biologics now has 20,000L SUB capacity across US sites and Taiwan.

Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ GMP biologics drug-substance manufacturing operations in Rockville, MD, plus a Frederick, MD warehousing center, for $122.5M via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics and now has 20,000L US SUB capacity across Rockville and San Diego.

MacroGenics (NASDAQ: MGNX) and Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) said the sale of MacroGenics’ GMP drug substance manufacturing operations to Bora has closed. Bora paid $122.5 million (before fees/expenses and post-closing adjustments). Bora assumed responsibility for Rockville, MD and Frederick, MD operations and hired about 140 employees; a supply agreement covers process development and drug substance production for MacroGenics’ pipeline needs.